In contrast, whereas the efficacy of olaparib monotherapy was compromised in mice bearing STING KO tumors, the combination was still efficacious in the absence of intratumoral STING, suggesting that STING agonism can favorably modulate the immune microenvironment to augment the activity of olaparib in an immunocompetent BRCA1-deficient BC model. The gene discussed is BRCA1; the disease is breast cancer.